placebo + acarbose

Placebo + acarbose refers to a specific treatment arm used in clinical research, notably in Phase 4 trials (such as NCT01490918) evaluating third-line therapies for type 2 diabetes mellitus (T2DM). In this context, the regimen consists of a placebo (specifically a placebo for metformin) administered alongside the active drug acarbose. Acarbose is a small molecule alpha-glucosidase inhibitor that works by competitively inhibiting enzymes in the brush border of the small intestine, thereby slowing the digestion of carbohydrates and reducing postprandial blood glucose elevations. This combination is typically used in randomized, double-blind studies to isolate the efficacy and safety of adding acarbose to existing regimens (like sitagliptin) in patients whose diabetes is inadequately controlled by metformin and DPP-4 inhibitors.

Other names

metformin placebo + acarboseSita+Acarb exploratory group